Epilepsy Research
Volume 29, Issue 2 , Pages 155-160 , January 1998

A comparison of the neuropathological effects of vigabatrin and carbamazepine in patients with newly diagnosed localization-related epilepsy using MR-based cerebral T2 relaxation time measurements

  • W Van Paesschen

      Affiliations

    • Epilepsy Research Group, University Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    • NMR Unit, Great Ormond Street Hospital for Children and Institute of Child Health, 30 Guilford Street, London WC1N 3JH, UK
    • Corresponding Author InformationCorresponding author. Present address: Department of Neurology, University Hospital Gasthuisberg, 49 Herestraat, 3000 Leuven, Belgium. Tel.: +32 16 344280; fax: +32 16 344285.
    • ,
  • J.S Duncan

      Affiliations

    • Epilepsy Research Group, University Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    • ,
  • A Connelly

      Affiliations

    • NMR Unit, Great Ormond Street Hospital for Children and Institute of Child Health, 30 Guilford Street, London WC1N 3JH, UK

Received 27 April 1997 ,Revised 10 September 1997 ,Accepted 14 September 1997.

References 

  1. Agosti R, Yasargil G, Egli M, Wieser HG, Wiestler OD. Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles. Epilepsy Res. 1990;6:166–170
  2. Arezzo JC, Schroeder CE, Litwak MS, Steward DL. Effects of vigabatrin on evoked potentials in dogs. Br J Clin Pharmacol. 1989;27(Suppl 1):S53–60
  3. Butler WH. The neuropathology of vigabatrin. Epilepsia. 1989;30(Suppl 3):S15–17
  4. Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol. 1987;15:143–148
  5. Cannon DJ, Butler WH, Mumford JP, Lewis PJ. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol 1991; Suppl 2:S17–24.
  6. Cocito L, Maffini M, Loeb C. MRI findings in epileptic patients on vigabatrin for more than 5 years. Seizure. 1992;1:163–165
  7. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489–501.
  8. Cosi V, Callieco R, Galimberti CA, Manni R, Tartara A, Mumford J, et al. Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol. 1989;27(Suppl 1):S61–68
  9. Dodrill CB, Arnett JL, Sommerville KW, Sussman NM. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology. 1993;43:2501–2507
  10. French JA, Mosier M, Walker S, Sommerville K, Sussman N. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology. 1996;46:54–61
  11. Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JW. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol. 1990;18:225–238
  12. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol. 1989;27(Suppl 1):S43–45
  13. Grünewald RA, Thompson PJ, Corcoran R, Corden Z, Jackson GD, Duncan JS. Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry. 1994;57:1057–1063
  14. Hammond EJ, Ballinger WE, Lu L, Wilder BJ, Uthman BM, Reid SA. Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy. Epilepsy Res. 1992;12:261–265
  15. Hammond EJ, Rangel RJ, Wilder BJ. Evoked potential monitoring of vigabatrin patients. Br J Clin Pract Symp Suppl 1988;61:S16–23.
  16. Hammond EJ, Wilder BJ. Effect of gamma-vinyl GABA on human pattern evoked visual potentials. Neurology. 1985;35:1801–1803
  17. Jackson GD, Connelly A, Duncan JS, Grünewald RA, Gadian DG. Detection of hippocampal pathology in intractable partial epilepsy: increased sensitivity with quantitative magnetic resonance T2 relaxometry. Neurology. 1993;43:1793–1799
  18. Jackson GD, Grünewald RA, Connelly A, Duncan JS. Quantitative MR relaxometry study of effects of vigabatrin on the brains of patients with epilepsy. Epilepsy Res. 1994;18:127–137
  19. Jackson GD, Williams SR, Weller RO, van Buggen N, Preece NE, Williams SC, et al. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res. 1994;18:57–66
  20. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol. 1995;52:989–996
  21. Liegeois Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P. Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients. Epilepsia. 1989;30(Suppl 3):S23–25
  22. Norusis MJ. SPSS for Windows: Base System User's Guide, Release 6. USA:SPSS Inc. 1993.
  23. Pedersen B, Hojgaard K, Dam M. Vigabatrin: no microvacuoles in a human brain. Epilepsy Res. 1987;1:74–76
  24. Peyster RG, Sussman NM, Hershey BL, et al.  Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia. 1995;36:93–100
  25. Sander JW, Trevisol Bittencourt PC, Hart YM, Shorvon SD. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J Neurol Neurosurg Psychiatry. 1990;53:1008–1010
  26. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol. 1989;27(Suppl 1):S19–22
  27. Van Paesschen W, Revesz T, Duncan JS, King MD, Connelly A. Quantitative neuropathology and quantitative magnetic resonance imaging of the hippocampus in temporal lobe epilepsy. Ann Neurol 1997;42:756–66.
  28. Weiss KL, Schroeder CE, Kastin SJ, et al.  MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology. 1994;44:1944–1949
  29. Yarrington JT, Gibson JP, Dillberger JE, et al.  Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol. 1993;21:480–489

PII: S0920-1211(97)00077-6

Epilepsy Research
Volume 29, Issue 2 , Pages 155-160 , January 1998

Article Tools